Host cell environments and antibiotic efficacy in tuberculosis

Trends Microbiol. 2024 Mar;32(3):270-279. doi: 10.1016/j.tim.2023.08.009. Epub 2023 Sep 12.

Abstract

The aetiologic agent of tuberculosis (TB), Mycobacterium tuberculosis (Mtb), can survive, persist, and proliferate in a variety of heterogeneous subcellular compartments. Therefore, TB chemotherapy requires antibiotics crossing multiple biological membranes to reach distinct subcellular compartments and target these bacterial populations. These compartments are also dynamic, and our understanding of intracellular pharmacokinetics (PK) often represents a challenge for antitubercular drug development. In recent years, the development of high-resolution imaging approaches in the context of host-pathogen interactions has revealed the intracellular distribution of antibiotics at a new level, yielding discoveries with important clinical implications. In this review, we describe the current knowledge regarding cellular PK of antibiotics and the complexity of drug distribution within the context of TB. We also discuss the recent advances in quantitative imaging and highlight their applications for drug development in the context of how intracellular environments and microbial localisation affect TB treatment efficacy.

Keywords: antibiotic distribution; chemotherapy; intracellular pathogens; pharmacokinetics and pharmacodynamics; subcellular compartments; tuberculosis.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / metabolism
  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Host-Pathogen Interactions
  • Humans
  • Mycobacterium tuberculosis* / metabolism
  • Treatment Outcome
  • Tuberculosis* / drug therapy
  • Tuberculosis* / microbiology

Substances

  • Antitubercular Agents